Rheumatoid arthritis
Conditions
Interventions
Experimental Group:Tripterygium glycosides tablets, 20mg each time, three times a day, orally
Control group:Methotrexate tablets, 10mg each time, once a week, orally.
Sponsors
Beijing University of Chinese Medicine Dongzhimen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 72 Years
Inclusion criteria
Inclusion criteria: 1) Age: 18 to 72 years old, gender not limited. 2) 2.6 points < DAS28 score (active disease stage). 3) No hormone therapy was received within 12 weeks (including 12 weeks) before enrollment. 4) Those who have signed the informed consent form for clinical research and are willing to cooperate.
Exclusion criteria
Exclusion criteria: 1)Combined with other rheumatic immune diseases that may affect fatigue assessment, including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, systemic scleroderma, fibromyalgia syndrome, tensor spondylitis, etc.2)Patients who have been diagnosed with fatigue syndrome;3)Combined with severe respiratory system diseases, cardiovascular and cerebrovascular diseases, etc.4)Those with known mental disorders or allergic constitutions; 5) Suffering from any type of active malignant tumor or having a malignant tumor disease;6)Suffering from any acute or chronic active infectious disease;7)Patients who are preparing for pregnancy, pregnant or breastfeeding;8)Patients allergic to Tripterygium glycosides tablets;9)The researcher judged that it was not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of fatigue; | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate assessed by disease activity (predominantly DAS28-CRP);Fatigue Scale -14;ACR20 remission rate;Pain VAS score;Interleukin-6;Tumor necrosis factor-a; | — |
Countries
China
Contacts
Public ContactLV Liu
Dongzhimen Hospital of Beijing University of Chinese Medicine
Outcome results
None listed